VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Weekly semaglutide can help people living with type 1 diabetes “reach their blood sugar and weight goals”, new research has ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

Investing.com - Morgan Stanley (NYSE: MS) has reiterated an Equalweight rating and DKK550.00 price target on Novo Nordisk ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

IBI3030 significantly reduces LDL-c (p<0.01 vs. baseline) and Lp(a), improves oral glucose tolerance (OGTT) (effective even in GLP-1R knockout mice), reduces body weight, and preserves insulin ...

"For the outcome of MASH resolution without worsening fibrosis, the absolute differences in response rates versus placebo were 15% for dapagliflozin, 29% for semaglutide, and 20% for resmetirom ...

Metabolic dysfunction–associated steatohepatitis (MASH) is a form of liver disease that can progress to cirrhosis and hepatocellular carcinoma, but strategies for treating MASH are lacking ...

The bottom line For the millions of Americans living with fatty liver disease, particularly those with the more severe form known as MASH, semaglutide represents a promising new treatment option.

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.